hESC-Derived Cardiomyocyte Screening Platform Identifies Novel Inhibitors of SARS-Cov-2 Viral Entry


Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes COVID-19, the respiratory illness responsible for the COVID-19 pandemic. Studies have shown that patients infected with SARS-CoV-2 with cardiovascular comorbidities are more susceptible to severe infection and thus the case fatality rate in these patients rises. To further understand the pathology of SARS-CoV-2 in cardiomyocytes, a team of researchers from the University of Cambridge in the UK, have developed a screening platform using human embryonic stem cell-derived cardiomyocytes (hESC-CMs).